bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes

by Dale Harrison | Dec 28, 2022 | Articles, News

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes DECEMBER 28, 2022 As published in the The Fly By: Jessica de Sa-Mota BioAffinity focuses on the development of noninvasive, early-stage cancer diagnosis and targeted cancer treatment In an...

bioAffinity President & CEO to meet with institutional investors and bankers during J.P. Morgan Annual Healthcare Conference in San Francisco, January 9-12, 2023

by Dale Harrison | Dec 28, 2022 | Events

December 30, 2022 bioAffinity President & CEO Maria Zannes will meet with the institutional investors and investment banking groups while attending the WuXi Global Forum “Advancing Breakthroughs for Patients” during the J.P. Morgan 41st Annual Healthcare...

SA Cancer Diagnostic Company Adding Research Talent

by Dale Harrison | Dec 23, 2022 | Articles, News

SA Cancer Diagnostic Company Adding Research Talent DECEMBER 23, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. is making multiple personnel moves in an effort to...

Maria Zannes named to TEXAS 100 Influential professionals to watch in 2023

by Dale Harrison | Dec 21, 2022 | Articles, News

TEXAS 100 Influential professionals to watch in 2023 DECEMBER 21, 2022 As published in the San Antonio Business Journal By: Colin Pope – Editor, Austin Business Journal Our annual Texas 100 is a list of impactful Texans who will likely play crucial roles in the...

bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench

by Dale Harrison | Dec 15, 2022 | Press Releases

SAN ANTONIO, TX – Dec. 15, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that...
« Older Entries

Categories

  • Articles (28)
  • Events (38)
  • News (53)
  • Press Releases (138)
  • Publications (17)

Recent Posts

  • Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules September 9, 2025
  • U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA September 3, 2025
  • New Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA – US Medicine, the Voice of Federal Medicine August 29, 2025
  • bioAffinity Technologies Appoints New Members to Board of Directors August 18, 2025
  • bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds August 14, 2025
CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.